Showing 1591-1600 of 2042 results for "".
- Alcon Champions Access to Eye Care with Opening of Children’s Vision Center in Fort Worth, Texashttps://modernod.com/news/alcon-champions-access-to-eye-care-with-opening-of-childrens-vision-center-in-fort-worth-texas/2481337/Alcon announced the grand opening of the Alcon Children’s Vision Center. Located at 8376 Mojave Trail in Fort Worth, Texas, the center is a first-of-its-kind partnership between the Alcon Foundation and the Fort Worth Independent School District (FWISD). The center offers comprehensive
- Bausch + Lomb Introduces Enhanced PreserVision AREDS 2 Formula Mini Soft Gels with OCUSorbhttps://modernod.com/news/bausch-lomb-introduces-enhanced-preservision-areds-2-formula-mini-soft-gels-with-ocusorb/2481335/Bausch + Lomb announced the US introduction of PreserVision AREDS 2 Formula mini soft gels with OCUSorb. This product is the only AREDS 2 eye vitamin with the OCUSorb formulation. Offering a proprietary composition of lutein and zeaxanthin, Bausch + Lomb said OCUSorb has
- Harrow Announces Availability of Fortisite Formulations for In-Office Usehttps://modernod.com/news/harrow-announces-availability-of-fortisite-formulations-for-in-office-use/2481322/Harrow announced the availability, for in-office use, of Fortisite (compounded Tobramycin 1.5% + Vancomycin 5%) from its FDA‑registered and FDA‑inspected ImprimisRx 503B outsourcing facility. Fortisite formulations are patent-pending high-concentration, refrigeration-stable, f
- Study: Form of AMD Strongly Associated With Cardiovascular Diseasehttps://modernod.com/news/study-blinding-eye-disease-strongly-associated-with-serious-forms-of-cardiovascular-disease/2481254/Patients with a specific form of age-related macular degeneration (AMD) are also highly likely to have either underlying heart damage from heart failure and heart attacks, or advanced heart valve disease, or carotid artery disease associated with certain types of strokes, according to a new study
- ImprimisRx Launches Fortisite (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulationhttps://modernod.com/news/imprimisrx-launches-fortisite-tobramycin-15-vancomycin-5-compounded-antibiotic-formulation/2481135/ImprimisRx announced the availability of Fortisite, which includes a patent-pending compounded combination of Tobramycin 1.5% and Vancomycin 5%. Compounded topical antibiotic formulations may be appropriate to prescribe for patients with clinical needs that are unmet by FDA-
- Formosa Pharmaceuticals and AimMax Therapeutics Announce Topline Results from CPN-301 for the Treatment of Inflammation and Pain After Cataract Surgeryhttps://modernod.com/news/formosa-pharmaceuticals-and-aimmax-therapeutics-announce-successful-topline-results-from-cpn-301-for-the-treatment-of-inflammation-and-pain-after-cataract-surgery/2480937/Formosa Pharmaceuticals and AimMax Therapeutics reported successful topline results from CPN-301, the first of two pivotal phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of a corticosteroid, clobetasol propionate(0.05%), for the treatment of inflamma
- Skye Bioscience Reports Enhanced IOP-Lowering of SBI-100 Formulationhttps://modernod.com/news/skye-bioscience-reports-enhanced-iop-lowering-of-sbi-100-formulation/2480846/Skye Bioscience announced that the peer-reviewed journal International Journal of Pharmaceutics published preclinical data demonstrating stronger and longer-lasting reduction of IOP when Skye’s proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the
- Notal Vision Monitoring Center Reports AI Analysis of 10 Million ForeseeHome AMD Home Monitoring Testshttps://modernod.com/news/notal-vision-monitoring-center-reports-ai-analysis-of-10-million-foreseehome-amd-home-monitoring-tests/2480482/The Notal Vision Monitoring Center celebrates the artificial intelligence (AI) based analysis of the ten millionth test performed by over 20,000 patients with the FDA-cleared ForeseeHome devic
- Regeneron Terminates Ocular Therapeutix Collaboration to Develop a Sustained-Release Formulation of Aflibercepthttps://modernod.com/news/regeneron-terminates-ocular-therapeutix-collaboration-to-develop-a-sustained-release-formulation-of-aflibercept/2479441/Ocular Therapeutix announced that Regeneron has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021. The collaboration with Regeneron was initially formed in 2016 for the development and commercialization of produ
- EyePoint Pharmaceuticals Forms Executive Scientific Advisory Boardhttps://modernod.com/news/eyepoint-pharmaceuticals-forms-executive-scientific-advisory-board/2479426/EyePoint Pharmaceuticals announced the formation of its Executive Scientific Advisory Board (SAB), chaired by Carl Regillo MD, FACS, Chief of the Retina Service at Wills Eye Hospital. Other members of the SAB include Sophie J. Bakri, MD, Mayo Clinic; Caroline R. B